Insights Corner

NASDAQ: ABVC

Insights Corner

Integrating Botanical Drugs into Western Medicine

Integrating Botanical Drugs into Western Medicine 150 150 ABVC

https://www.youtube.com/watch?v=TYrNEA0mG-8 In this episode of Biotech Orbit, host Victor Lee speaks with our CEO, Dr. Utam Patil. Here he discusses our botanical-based therapies for major depressive disorder (MDD) and cancer. The conversation explores the unique advantages and regulatory challenges of botanical drugs, which are derived from natural plant and fungal sources. Dr. Patil shares that ABVC’s lead candidate for MDD, ABV-1504, is entering a Phase 3 clinical trial and has shown no signs of suicidal ideation or addiction which is a common concerns with synthetic antidepressants. This positions ABV-1504 as a promising alternative, particularly since it functions as a single…

𝗕𝗿𝗶𝗱𝗴𝗶𝗻𝗴 𝗧𝘄𝗼 𝗪𝗼𝗿𝗹𝗱𝘀: 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗳𝗼𝗿 𝗔𝘀𝗽𝗶𝗿𝗶𝗻𝗴 𝗣𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀 𝗮𝗻𝗱 𝗦𝘁𝘂𝗱𝗲𝗻𝘁𝘀 𝗖𝗼𝗻𝘀𝗶𝗱𝗲𝗿𝗶𝗻𝗴 𝗧𝗮𝗶𝘄𝗮𝗻

𝗕𝗿𝗶𝗱𝗴𝗶𝗻𝗴 𝗧𝘄𝗼 𝗪𝗼𝗿𝗹𝗱𝘀: 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗳𝗼𝗿 𝗔𝘀𝗽𝗶𝗿𝗶𝗻𝗴 𝗣𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀 𝗮𝗻𝗱 𝗦𝘁𝘂𝗱𝗲𝗻𝘁𝘀 𝗖𝗼𝗻𝘀𝗶𝗱𝗲𝗿𝗶𝗻𝗴 𝗧𝗮𝗶𝘄𝗮𝗻 1068 783 ABVC

As someone who moved to Taiwan over 14 years ago to pursue higher studies and later transitioned into a fulfilling career, I’m proud to represent the growing community of Indians working and living in Taiwan. My journey here has been one of learning, adaptation, and immense professional growth, and I’m keen to share insights with aspirants back in India who are considering Taiwan as a destination for education and work. 𝗪𝗵𝘆 𝗧𝗮𝗶𝘄𝗮𝗻? Taiwan offers a unique combination of high-quality education, advanced research opportunities, and a thriving job market. With its world-class universities and cutting-edge industries, it’s an ideal place for…

Indian Talent in Taiwan

Indian Talent in Taiwan 150 150 ABVC

Lots of Indians work and study in Taiwan! Dr. Priya is visiting some students and professionals currently working in Taiwan to see how they feel about their lives here. This episode highlights ABVC’s CEO Uttam Patil and some of our hardworking colleagues in our Taiwan office. https://www.youtube.com/watch?v=xLBStpD5BAI

All-Natural Treatment for Major Depressive Disorder (MDD) | ABV-1504

All-Natural Treatment for Major Depressive Disorder (MDD) | ABV-1504 150 150 ABVC

Summer 2024 Investor Presentation

View the latest product information, status updates, financial information, and more.

SAFE HARBOR STATEMENT

With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual future results of ABVC could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company’s operations, inability to hire and retain qualified personnel, and changes in the general economic climate. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by ABVC, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

Investor Considerations

  • Strong portfolio of medicines and medical devices addresses wide range of disorders.
  • In 2022, Vitargus is expected to begin a global pivotal trial, the final step leading to marketing in collaboration with big pharma licensing partners.
  • MDD drug intended to reduce adult depression completes Clinical Phase II with results exceeding expectations.
  • Botanical expertise leads to medicines with fewer side effects.
  • Partnerships with some of the most prestigious researchers in the world enhances the value of clinical trial results.
  • Business model designed to minimize burn rate.
  • Less than 30 million shares outstanding.

BACKGROUND

Leadership Team

NASDAQ: ABVC

Latest News

THERAPEUTIC FOCUS

Retinal Vitrectomy

Contact ABVC BioPharma

SOCIAL MEDIA

Facebook

LinkedIn

TELEPHONE

+1 845-291-1291

44370 Old Warm Springs Boulevard
Fremont, California 94538 USA
CONTACT FORM